bluebird bio Stock Price Target and Analyst Ratings (NASDAQ:BLUE)

Analyst Price Target for BLUE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$68.47

▲ +138.73% Upside Potential

This price target is based on 17 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $68.47, with a high forecast of $123.00 and a low forecast of $27.00. The average price target represents a 138.73% upside from the last price of $28.68.

Hold

The current consensus among 17 contributing investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

9/14/2019

0 strong buy ratings
7 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

12/13/2019

0 strong buy ratings
7 buy ratings
12 hold ratings
0 sell ratings

Ratings as of

3/12/2020

0 strong buy ratings
6 buy ratings
14 hold ratings
0 sell ratings

Ratings as of

6/10/2020

0 strong buy ratings
5 buy ratings
13 hold ratings
0 sell ratings

Ratings as of

9/8/2020

0 strong buy ratings
5 buy ratings
13 hold ratings
0 sell ratings

Ratings as of

12/7/2020

0 strong buy ratings
4 buy ratings
14 hold ratings
0 sell ratings

Ratings as of

2/5/2021

0 strong buy ratings
4 buy ratings
13 hold ratings
0 sell ratings

Ratings as of

3/7/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/2/2021	Morgan Stanley	Lower Price Target	Equal Weight	$50.00 ➝ $45.00	Medium	i
2/24/2021	Barclays	Lower Price Target	Equal Weight	$31.00 ➝ $27.00	Medium	i
2/17/2021	BMO Capital Markets	Boost Price Target	Market Perform	$36.00 ➝ $56.00	Low	i
2/17/2021	Stifel Nicolaus	Lower Price Target	Hold	$48.00 ➝ $35.00	Low	i
2/17/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform		Low	i
2/17/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$76.00 ➝ $39.00	Low	i
2/16/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/16/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low	i
2/16/2021	Wedbush	Downgrade	Outperform ➝ Neutral		Low	i Rating by D. Nierengarten at Wedbush
2/16/2021	Mizuho	Downgrade	Buy ➝ Neutral		Low	i
2/16/2021	Piper Sandler	Lower Price Target	Neutral	$55.00 ➝ $35.00	Low	i
2/16/2021	William Blair	Downgrade	Outperform ➝ Market Perform		Low	i Rating by R. Prasad at William Blair
12/9/2020	Maxim Group	Downgrade	Buy ➝ Hold		High	i
12/7/2020	Mizuho	Reiterated Rating	Buy		High	i
11/11/2020	Berenberg Bank	Initiated Coverage	Buy	$64.00	Low	i
11/11/2020	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $50.00	Low	i
11/6/2020	Wedbush	Lower Price Target	Outperform	$81.00 ➝ $73.00	Medium	i
11/5/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$77.00 ➝ $51.00	Medium	i
11/5/2020	Barclays	Downgrade	Overweight ➝ Equal Weight		High	i
11/5/2020	Canaccord Genuity	Lower Price Target	Buy	$118.00 ➝ $86.00	High	i
11/5/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$140.00 ➝ $76.00	High	i
11/5/2020	Wells Fargo & Company	Lower Price Target	Overweight	$94.00 ➝ $81.00	High	i
11/5/2020	SVB Leerink	Lower Price Target	Outperform	$133.00 ➝ $99.00	High	i
11/5/2020	Bank of America	Lower Price Target	Buy	$100.00 ➝ $81.00	High	i
11/5/2020	Royal Bank of Canada	Lower Price Target	Outperform	$100.00 ➝ $93.00	High	i
11/5/2020	Oppenheimer	Lower Price Target	Outperform	$111.00 ➝ $90.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/5/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$108.00 ➝ $56.00	High	i
11/4/2020	Piper Sandler	Lower Price Target	Neutral	$70.00 ➝ $55.00	High	i
11/2/2020	William Blair	Upgrade	Market Perform ➝ Outperform		Medium	i Rating by R. Prasad at William Blair
10/19/2020	Mizuho	Initiated Coverage	Buy	$123.00	Medium	i
8/31/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/30/2020	William Blair	Reiterated Rating	Hold		High	i
8/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium	i
8/10/2020	Morgan Stanley	Lower Price Target	Equal Weight	$73.00 ➝ $68.00	Medium	i
8/6/2020	BMO Capital Markets	Lower Price Target	Outperform	$112.00 ➝ $108.00	High	i
8/6/2020	Wedbush	Lower Price Target	Outperform	$89.00 ➝ $81.00	Medium	i
7/29/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
7/13/2020	Bank of America	Lower Price Target	Buy	$104.00 ➝ $100.00	High	i
6/12/2020	SVB Leerink	Boost Price Target	Outperform	$129.00 ➝ $133.00	Medium	i
6/1/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/28/2020	Morgan Stanley	Boost Price Target	Equal Weight	$69.00 ➝ $73.00	Medium	i
5/28/2020	SVB Leerink	Boost Price Target	Outperform	$125.00 ➝ $129.00	Low	i
5/17/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Medium	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/13/2020	Barclays	Reiterated Rating	Buy		High	i
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$100.00	High	i
5/12/2020	Canaccord Genuity	Reiterated Rating	Buy	$118.00	High	i
5/12/2020	BMO Capital Markets	Boost Price Target	Outperform	$107.00 ➝ $112.00	High	i
5/11/2020	Oppenheimer	Initiated Coverage	Buy	$122.00 ➝ $111.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/11/2020	Piper Sandler	Lower Price Target	Neutral	$75.00 ➝ $70.00	High	i
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$92.00 ➝ $69.00	Low	i Rating by Matthew Harrison at Morgan Stanley
3/27/2020	BMO Capital Markets	Lower Price Target	Outperform	$132.00 ➝ $107.00	Low	i
3/27/2020	William Blair	Reiterated Rating	Hold		Medium	i
3/26/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$94.00 ➝ $70.00	Low	i Rating by Benjamin Burnett at Stifel Nicolaus
3/26/2020	Piper Sandler	Lower Price Target		$85.00 ➝ $75.00	Low	i
3/26/2020	Wells Fargo & Company	Reiterated Rating	Buy		Medium	i
2/26/2020	Morgan Stanley	Lower Price Target	Equal Weight	$100.00 ➝ $92.00	Low	i Rating by Matthew Harrison at Morgan Stanley
2/20/2020	Oppenheimer	Lower Price Target		$135.00 ➝ $128.00	Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/19/2020	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High	i
2/19/2020	Stifel Nicolaus	Lower Price Target	Hold	$96.00 ➝ $94.00	High	i Rating by Benjamin Burnett at Stifel Nicolaus
2/3/2020	Bank of America	Initiated Coverage	Buy	$120.00	High	i
2/3/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$86.00 ➝ $100.00	High	i
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium	i
12/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$135.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/10/2019	William Blair	Reiterated Rating	Hold		High	i Rating by Raju Prasad at William Blair
12/9/2019	Wells Fargo & Company	Lower Price Target	Overweight	$242.00 ➝ $160.00	High	i
12/9/2019	Canaccord Genuity	Lower Price Target	Buy	$171.00 ➝ $118.00	High	i
12/6/2019	Cowen	Reiterated Rating	Buy		Low	i
11/27/2019	Evercore ISI	Downgrade	Outperform ➝ In-Line		Medium	i
11/26/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$119.00	Low	i Rating by M. Foroohar at SVB Leerink LLC
11/21/2019	Cowen	Reiterated Rating	Buy		Medium	i
11/4/2019	Wedbush	Upgrade	Neutral ➝ Outperform	$131.00 ➝ $124.00	High	i Rating by D. Nierengarten at Wedbush
11/1/2019	Stifel Nicolaus	Set Price Target	Hold	$96.00	Low	i Rating by Benjamin Burnett at Stifel Nicolaus
11/1/2019	Morgan Stanley	Set Price Target	Hold	$104.00 ➝ $100.00	Low	i Rating by Matthew Harrison at Morgan Stanley
11/1/2019	Maxim Group	Reiterated Rating	Buy	$130.00	Low	i
10/11/2019	Morgan Stanley	Lower Price Target	Equal Weight	$136.00 ➝ $104.00	Medium	i
10/9/2019	Stifel Nicolaus	Reiterated Rating	Hold		N/A	i Rating by Benjamin Burnett at Stifel Nicolaus
9/30/2019	Stifel Nicolaus	Initiated Coverage	Hold	$109.00	High	i
9/18/2019	William Blair	Reiterated Rating	Hold		Low	i Rating by R. Prasad at William Blair
8/12/2019	William Blair	Downgrade	Outperform ➝ Market Perform		High	i Rating by R. Prasad at William Blair
8/6/2019	Morgan Stanley	Lower Price Target	Equal Weight	$143.00 ➝ $136.00	Medium	i
7/19/2019	Gabelli	Reiterated Rating	Buy		N/A	i Rating by Jing He at Gabelli
6/18/2019	Maxim Group	Upgrade	Hold ➝ Buy	$160.00	High	i
6/17/2019	BMO Capital Markets	Lower Price Target	Outperform	$191.00 ➝ $163.00	Low	i Rating by Matthew Luchini at BMO Capital Markets
6/14/2019	Piper Jaffray Companies	Set Price Target	Hold	$120.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
6/13/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$195.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
5/17/2019	JPMorgan Chase & Co.	Set Price Target	Buy	$195.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
5/16/2019	SunTrust Banks	Lower Price Target	Buy	$174.00	Medium	i
5/15/2019	Wedbush	Downgrade	Outperform ➝ Neutral	$166.00 ➝ $131.00	Medium	i Rating by D. Nierengarten at Wedbush
5/3/2019	BMO Capital Markets	Set Price Target	Buy	$191.00	High	i Rating by Matthew Luchini at BMO Capital Markets
5/3/2019	William Blair	Reiterated Rating	Buy		Medium	i Rating by R. Prasad at William Blair
4/23/2019	William Blair	Reiterated Rating	Outperform		Low	i Rating by R. Prasad at William Blair
3/22/2019	Cantor Fitzgerald	Set Price Target	Hold	$122.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
3/5/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low	i Rating by M. Foroohar at SVB Leerink LLC
2/26/2019	Cowen	Initiated Coverage	Outperform	$149.91	High	i Rating by Chris Shibutani at Cowen Inc
2/25/2019	SunTrust Banks	Lower Price Target	Buy	$184.00	High	i
2/22/2019	BMO Capital Markets	Boost Price Target	Outperform	$194.00	Medium	i
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$134.00 ➝ $122.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
1/23/2019	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $161.00	High	i
1/11/2019	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High	i
12/19/2018	Raymond James	Initiated Coverage	Strong-Buy ➝ Strong-Buy	$165.00	High	i
12/9/2018	Cowen	Reiterated Rating	Buy		Low	i Rating by Chris Shibutani at Cowen Inc
12/6/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$240.00 ➝ $120.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
12/4/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/4/2018	William Blair	Reiterated Rating	Buy		Low	i Rating by Raju Prasad at William Blair
12/3/2018	Janney Montgomery Scott	Set Price Target	Outperform ➝ Buy	$170.00	High	i Rating by Yun Zhong at Janney Montgomery Scott
12/3/2018	Maxim Group	Reiterated Rating	Hold		High	i Rating by Jason McCarthy at Maxim Group
12/3/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$134.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
11/27/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/27/2018	SVB Leerink	Initiated Coverage	Outperform	$145.00 ➝ $145.00	Low	i Rating by M. Foroohar at SVB Leerink LLC
11/14/2018	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$155.00	High	i
11/5/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$186.00 ➝ $185.00	Low	i
11/5/2018	Wedbush	Lower Price Target	Outperform ➝ Outperform	$204.00 ➝ $166.00	Medium	i
11/5/2018	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$170.00 ➝ $170.00	Medium	i Rating by Yun Zhong at Janney Montgomery Scott
11/4/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
11/2/2018	Cowen	Reiterated Rating	Buy		Medium	i
11/2/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/2/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Neutral	$122.00 ➝ $134.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
11/1/2018	Maxim Group	Reiterated Rating	Hold		Medium	i
11/1/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
10/15/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $186.00	Low	i
9/21/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Medium	i
9/17/2018	Guggenheim	Initiated Coverage	Neutral		Medium	i
9/5/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
9/5/2018	William Blair	Reiterated Rating	Buy		Medium	i Rating by Raju Prasad at William Blair
8/23/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
8/6/2018	Maxim Group	Reiterated Rating	Hold		Low	i Rating by Jason McCarthy at Maxim Group
8/6/2018	Cowen	Reiterated Rating	Buy		Low	i
8/6/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
8/3/2018	SunTrust Banks	Reiterated Rating	Buy	$223.00	High	i
8/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$208.00	High	i Rating by Matthew Luchini at BMO Capital Markets
8/2/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
7/30/2018	Maxim Group	Lower Price Target	Hold	$163.00	Low	i Rating by Jason McCarthy at Maxim Group
7/13/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
7/12/2018	Gabelli	Initiated Coverage	Buy	$239.00	Low	i Rating by J. He at Gabelli
6/19/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform	$175.00 ➝ $230.00	Low	i
6/5/2018	Piper Jaffray Companies	Set Price Target	Buy	$240.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
6/4/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Overweight		Low	i Rating by E. Piros at Cantor Fitzgerald
6/4/2018	Cowen	Reiterated Rating	Buy		High	i
6/3/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
5/30/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Buy	$240.00	High	i Rating by Tyler Van Buren at Piper Jaffray Companies
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Underweight		Low	i Rating by E. Piros at Cantor Fitzgerald
5/10/2018	Cantor Fitzgerald	Reiterated Rating	Sell	$122.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
5/7/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$211.00	Low	i Rating by Vincent Chen at Sanford C. Bernstein
5/3/2018	Maxim Group	Set Price Target	Hold	$200.00	High	i Rating by Jason McCarthy at Maxim Group
5/3/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Buy	$222.00 ➝ $216.00	High	i Rating by Matthew Luchini at BMO Capital Markets
5/3/2018	BTIG Research	Reiterated Rating	Buy		High	i
4/19/2018	SunTrust Banks	Boost Price Target	Buy	$232.00	High	i
3/28/2018	Canaccord Genuity	Reiterated Rating	Buy		Low	i Rating by John Newman at Canaccord Genuity
3/21/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$152.00 ➝ $209.00	High	i
3/16/2018	William Blair	Reiterated Rating	Buy		Medium	i Rating by Raju Prasad at William Blair
3/16/2018	UBS Group	Initiated Coverage	Sell		High	i
3/14/2018	Janney Montgomery Scott	Initiated Coverage	Neutral ➝ Neutral	$220.00	Medium	i
3/13/2018	Canaccord Genuity	Reiterated Rating	Buy	$250.00	Low	i Rating by John Newman at Canaccord Genuity
3/8/2018	BTIG Research	Boost Price Target	Buy	$250.00	Medium	i
3/5/2018	William Blair	Initiated Coverage	Outperform ➝ Outperform	$206.10 ➝ $242.00	High	i Rating by Raju Prasad at William Blair
2/26/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$151.00 ➝ $152.00	Medium	i
2/22/2018	Maxim Group	Reiterated Rating	Hold	$200.00	Medium	i Rating by Jason McCarthy at Maxim Group
2/22/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$185.00 ➝ $218.00	Medium	i
2/22/2018	BMO Capital Markets	Set Price Target	Outperform ➝ Buy	$215.00 ➝ $222.00	High	i Rating by Matthew Luchini at BMO Capital Markets
2/22/2018	Sanford C. Bernstein	Reiterated Rating	Hold	$153.00 ➝ $211.00	High	i
2/22/2018	Cantor Fitzgerald	Lower Price Target	Underweight	$122.00 ➝ $113.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
2/21/2018	Cantor Fitzgerald	Reiterated Rating	Underweight ➝ Sell	$122.00 ➝ $113.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
2/1/2018	Canaccord Genuity	Reiterated Rating	Buy	$250.00	High	i Rating by John Newman at Canaccord Genuity
1/25/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $194.00	Low	i Rating by M. Schmidt at SVB Leerink LLC
1/9/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/21/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		High	i
12/20/2017	Oppenheimer	Initiated Coverage	Market Perform		Low	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/13/2017	Maxim Group	Downgrade	Buy ➝ Hold	$200.00	Medium	i Rating by Jason McCarthy at Maxim Group
12/13/2017	Barclays	Reiterated Rating	Overweight ➝ Overweight	$162.00 ➝ $209.00	High	i
12/12/2017	SunTrust Banks	Boost Price Target	Buy	$223.00	High	i
12/12/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$190.00 ➝ $242.00	High	i
12/11/2017	BMO Capital Markets	Set Price Target	Buy	$215.00	High	i Rating by Matthew Luchini at BMO Capital Markets
12/11/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$130.00 ➝ $211.00	High	i
12/11/2017	Cantor Fitzgerald	Set Price Target	Underweight ➝ Underweight	$58.00 ➝ $113.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
12/5/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$202.00	Low	i
11/30/2017	Maxim Group	Boost Price Target	Buy ➝ Buy	$170.00 ➝ $200.00	High	i Rating by Jason McCarthy at Maxim Group
11/17/2017	Maxim Group	Set Price Target	Buy	$170.00	N/A	i Rating by Jason McCarthy at Maxim Group
11/3/2017	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$108.00 ➝ $163.00	N/A	i
11/3/2017	Jefferies Financial Group	Reiterated Rating	Hold	$130.00	N/A	i
11/3/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		N/A	i
11/2/2017	Barclays	Boost Price Target	Overweight	$151.00 ➝ $162.00	N/A	i
11/2/2017	Maxim Group	Reiterated Rating	Buy	$170.00	N/A	i Rating by Jason McCarthy at Maxim Group
11/2/2017	Wedbush	Reiterated Rating	Outperform	$135.00 ➝ $174.00	N/A	i
11/2/2017	BTIG Research	Upgrade	Neutral ➝ Buy	$177.00	N/A	i
11/1/2017	SVB Leerink	Reiterated Rating	Outperform	$145.00 ➝ $162.00	N/A	i
11/1/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00 ➝ $58.00	N/A	i Rating by Elemer Piros at Cantor Fitzgerald
10/30/2017	BMO Capital Markets	Boost Price Target	Buy	$134.00 ➝ $162.00	N/A	i Rating by Matthew Luchini at BMO Capital Markets
10/16/2017	Evercore ISI	Upgrade	In-Line ➝ Outperform	$102.00	N/A	i
10/11/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold	$126.00	N/A	i
10/9/2017	Maxim Group	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $170.00	N/A	i Rating by Jason McCarthy at Maxim Group
10/6/2017	SVB Leerink	Reiterated Rating	Outperform	$120.00 ➝ $145.00	N/A	i
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$186.00	N/A	i
10/2/2017	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$105.00	High	i
9/30/2017	SVB Leerink	Reiterated Rating	Outperform	$120.00	High	i
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
9/6/2017	Barclays	Initiated Coverage	Overweight	$151.00	Low	i
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform ➝ Outperform	$134.00 ➝ $158.00	Medium	i
9/1/2017	Wedbush	Reiterated Rating	Outperform	$121.00 ➝ $135.00	High	i
8/31/2017	Cowen	Reiterated Rating	Outperform		High	i
8/16/2017	Evercore ISI	Initiated Coverage	In ➝ In-Line	$102.00	High	i
8/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	Medium	i
8/9/2017	Morgan Stanley	Reiterated Rating	Hold		High	i
8/7/2017	Morgan Stanley	Boost Price Target	Equal ➝ Equal Weight	$103.00 ➝ $105.00	Medium	i
8/4/2017	BMO Capital Markets	Reiterated Rating	Buy	$108.00	Medium	i Rating by Matthew Luchini at BMO Capital Markets
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$109.00	High	i
7/24/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$105.00 ➝ $103.00	Low	i
7/6/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
6/30/2017	BTIG Research	Downgrade	Buy ➝ Neutral	$37.05 ➝ $108.25	Medium	i
6/28/2017	BTIG Research	Reiterated Rating	Buy ➝ Buy	$112.00	High	i
6/26/2017	Janney Montgomery Scott	Set Price Target	Buy	$125.00	N/A	i Rating by Debjit Chattopadhyay at Janney Montgomery Scott
6/24/2017	Cantor Fitzgerald	Set Price Target	Sell	$37.00 ➝ $39.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
6/23/2017	Cowen	Reiterated Rating	Buy		Low	i
6/23/2017	Wedbush	Reiterated Rating	Outperform	$121.00 ➝ $100.00	Low	i
6/16/2017	Standpoint Research	Reiterated Rating	Buy ➝ Reduce	$110.00	Low	i
6/14/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$91.00 ➝ $105.00	Low	i
6/9/2017	Cowen	Reiterated Rating	Outperform		Low	i
6/7/2017	Janney Montgomery Scott	Boost Price Target	Neutral ➝ Buy	$81.00 ➝ $125.00	High	i
6/6/2017	Wedbush	Reiterated Rating	Outperform		High	i
6/6/2017	BMO Capital Markets	Reiterated Rating	Buy	$108.00	High	i
6/5/2017	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$61.00 ➝ $108.00	High	i
6/5/2017	Bank of America	Reiterated Rating	Hold	$95.00	High	i
6/5/2017	Cantor Fitzgerald	Set Price Target	Sell	$37.00	High	i
6/2/2017	Maxim Group	Upgrade	Hold ➝ Buy	$100.00	High	i Rating by Jason McCarthy at Maxim Group
6/1/2017	BTIG Research	Reiterated Rating	Buy	$112.00	High	i
5/30/2017	Standpoint Research	Initiated Coverage	Buy ➝ Buy	$110.00	Low	i
5/15/2017	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
5/8/2017	Morgan Stanley	Boost Price Target	Equal Weight	$87.00 ➝ $91.00	Medium	i
5/5/2017	Maxim Group	Reiterated Rating	Hold		High	i Rating by Jason McCarthy at Maxim Group
5/1/2017	BTIG Research	Reiterated Rating	Buy		Medium	i
3/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	High	i Rating by Gena Wang at Jefferies Financial Group Inc.
3/1/2017	Morgan Stanley	Boost Price Target	Equal Weight	$58.00 ➝ $87.00	N/A	i
2/27/2017	Maxim Group	Downgrade	Buy ➝ Hold	$87.00	N/A	i Rating by Jason McCarthy at Maxim Group
2/23/2017	Roth Capital	Set Price Target	Hold	$71.00	N/A	i Rating by Mark Breidenbach at Roth Capital
2/23/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$83.00	N/A	i Rating by Matthew Luchini at BMO Capital Markets
2/6/2017	Roth Capital	Reiterated Rating	Buy ➝ Neutral	$87.00 ➝ $71.00	N/A	i Rating by Mark Breidenbach at Roth Capital
2/3/2017	Maxim Group	Set Price Target	Buy	$87.00	N/A	i Rating by Jason McCarthy at Maxim Group
1/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
12/15/2016	Roth Capital	Reiterated Rating	Buy	$87.00	N/A	i Rating by Mark Breidenbach at Roth Capital
12/13/2016	Maxim Group	Reiterated Rating	Buy	$87.00	N/A	i Rating by Jason McCarthy at Maxim Group
12/12/2016	Jefferies Financial Group	Set Price Target	Buy	$88.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
12/10/2016	Cantor Fitzgerald	Reiterated Rating	Sell		N/A	i Rating by E. Piros at Cantor Fitzgerald
12/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$120.00	N/A	i
12/4/2016	Bank of America	Reiterated Rating	Neutral	$68.00	N/A	i
12/1/2016	SVB Leerink	Boost Price Target	Outperform	$80.00 ➝ $85.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
12/1/2016	Wedbush	Reiterated Rating	Outperform	$95.00	N/A	i
12/1/2016	BMO Capital Markets	Set Price Target	Hold	$61.00 ➝ $83.00	N/A	i Rating by Matthew Luchini at BMO Capital Markets
12/1/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00 ➝ $88.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
12/1/2016	Roth Capital	Set Price Target	Buy	$87.00	N/A	i Rating by Mark Breidenbach at Roth Capital
12/1/2016	Maxim Group	Boost Price Target	Buy	$57.00 ➝ $87.00	N/A	i Rating by Jason McCarthy at Maxim Group
12/1/2016	Cantor Fitzgerald	Reiterated Rating	Sell	$37.00	N/A	i Rating by E. Piros at Cantor Fitzgerald
12/1/2016	BTIG Research	Reiterated Rating	Buy	$83.00	N/A	i Rating by Dane Leone at BTIG Research
11/30/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$95.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/24/2016	Janney Montgomery Scott	Reiterated Rating	Buy		N/A	i Rating by Debjit Chattopadhyay at Janney Montgomery Scott
11/24/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/23/2016	Wedbush	Reiterated Rating	Outperform	$95.00	N/A	i
11/10/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$61.00	N/A	i
11/7/2016	BTIG Research	Reiterated Rating	Buy	$83.00	N/A	i Rating by Dane Leone at BTIG Research
11/7/2016	SVB Leerink	Reiterated Rating	Outperform	$80.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
11/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
11/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$95.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/3/2016	Wedbush	Reiterated Rating	Outperform	$95.00 ➝ $117.00	N/A	i
11/3/2016	Cantor Fitzgerald	Reiterated Rating	Sell	$37.00	N/A	i Rating by E. Piros at Cantor Fitzgerald
10/25/2016	Piper Jaffray Companies	Set Price Target	Buy	$95.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
10/17/2016	Cowen	Reiterated Rating	Outperform		N/A	i
10/15/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
10/15/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$135.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
10/15/2016	BTIG Research	Reiterated Rating	Buy	$72.00 ➝ $83.00	N/A	i Rating by Dane Leone at BTIG Research
10/14/2016	SVB Leerink	Boost Price Target	Outperform	$67.00 ➝ $80.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
10/14/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A	i
10/14/2016	Cantor Fitzgerald	Downgrade	Hold ➝ Sell	$65.24 ➝ $37.00	N/A	i Rating by E. Piros at Cantor Fitzgerald
10/14/2016	SunTrust Banks	Reiterated Rating	Buy		N/A	i
10/13/2016	Piper Jaffray Companies	Set Price Target	Buy	$95.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
10/3/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A	i
9/30/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A	i
9/29/2016	Maxim Group	Set Price Target	Buy	$85.00 ➝ $100.00	N/A	i Rating by jason mccarthy at Maxim Group
9/23/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A	i
9/22/2016	Maxim Group	Set Price Target	Buy	$85.00	N/A	i Rating by jason mccarthy at Maxim Group
9/22/2016	Roth Capital	Initiated Coverage	Buy	$87.00	N/A	i Rating by M. Breidenbach at Roth Capital
9/15/2016	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$135.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
9/12/2016	Maxim Group	Reiterated Rating	Buy	$85.00	N/A	i Rating by Jason McCarthy at Maxim Group
9/11/2016	BTIG Research	Reiterated Rating	Buy	$72.00	N/A	i Rating by Dane Leone at BTIG Research
9/9/2016	Cowen	Reiterated Rating	Outperform		N/A	i
9/9/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Michael Schmidt at SVB Leerink LLC
9/8/2016	Piper Jaffray Companies	Set Price Target	Buy	$95.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
9/8/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A	i
9/8/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$135.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/18/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$135.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/18/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$117.00 ➝ $95.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
8/4/2016	SVB Leerink	Reiterated Rating	Outperform	$67.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
8/4/2016	Maxim Group	Reiterated Rating	Buy	$105.00 ➝ $85.00	N/A	i Rating by Jason McCarthy at Maxim Group
8/3/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A	i
7/14/2016	Jefferies Financial Group	Reiterated Rating	Positive	$80.00	N/A	i
7/8/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A	i
6/29/2016	BTIG Research	Reiterated Rating	Buy	$72.00	N/A	i Rating by Dane Leone at BTIG Research
6/13/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Michael Schmidt at SVB Leerink LLC
6/2/2016	Cantor Fitzgerald	Initiated Coverage	Hold	$42.00	N/A	i Rating by E. Piros at Cantor Fitzgerald
5/11/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$117.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
5/10/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$91.00	N/A	i Rating by Debjit Chattopadhyay at Janney Montgomery Scott
5/7/2016	Jefferies Financial Group	Reiterated Rating	Buy	$84.00 ➝ $80.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
5/7/2016	BTIG Research	Reiterated Rating	Buy	$72.00	N/A	i Rating by Dane Leone at BTIG Research
5/5/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i
5/5/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A	i
4/23/2016	The Goldman Sachs Group	Reiterated Rating	Neutral	$149.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
4/20/2016	Maxim Group	Reiterated Rating	Buy	$105.00	N/A	i Rating by Jason McCarthy at Maxim Group
4/20/2016	BTIG Research	Reiterated Rating	Buy	$72.00	N/A	i Rating by Dane Leone at BTIG Research
4/11/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$149.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
4/5/2016	SVB Leerink	Reiterated Rating	Outperform	$67.00	N/A	i
4/3/2016	BTIG Research	Reiterated Rating	Buy	$72.00	N/A	i Rating by Dane Leone at BTIG Research
3/19/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$117.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies

(Data available from 3/7/2016 forward)

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of Ã-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $28.68

$26.18

$28.76

50 Day Range

MA: $40.74

$25.62

$51.85

52 Week Range

Now: $28.68

$24.24

$72.50

Volume

1,708,384 shs

Average Volume

2,407,888 shs

Market Capitalization

$1.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Canaccord Genuity, JPMorgan Chase & Co., Maxim Group, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, Wedbush, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

15 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $68.47, suggesting a possible upside of 138.7%. Mizuho has the highest price target set, predicting BLUE will reach $123.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $27.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 13 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

Other companies that are similar to bluebird bio include Denali Therapeutics, Adaptive Biotechnologies, Vir Biotechnology, Twist Bioscience, Halozyme Therapeutics, Kodiak Sciences, Allogene Therapeutics, Iovance Biotherapeutics, China Biologic Products, Beam Therapeutics, Ablynx, SpringWorks Therapeutics, Relay Therapeutics, Revolution Medicines and NantKwest.

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is 339-499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com.

NASDAQ:BLUE - bluebird bio Stock Price Target and Predictions

Analyst Price Target for BLUE

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

What is the current price target for bluebird bio?

What is the current consensus analyst rating for bluebird bio?

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?